EXANE DERIVATIVES - CTI BIOPHARMA CORP ownership

CTI BIOPHARMA CORP's ticker is CTICXXXX and the CUSIP is 12648L106. A total of 63 filers reported holding CTI BIOPHARMA CORP in Q3 2016. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
EXANE DERIVATIVES ownership history of CTI BIOPHARMA CORP
ValueSharesWeighting
Q3 2016$010.0%0.00%
Q2 2016$0
-100.0%
10.0%0.00%
Q1 2016$1,0000.0%10.0%0.00%
Q4 2015$1,0000.0%10.0%0.00%
Q3 2015$1,000
-99.8%
1
-99.7%
0.00%
Q2 2015$596,000
+5.1%
3000.0%0.00%
Q1 2015$567,000
-19.0%
3000.0%0.00%
Q4 2014$700,0003000.00%
Other shareholders
CTI BIOPHARMA CORP shareholders Q3 2016
NameSharesValueWeighting ↓
BVF INC/IL 44,796,940$16,767,0003.16%
Nine Chapters Capital Management LLC 24,900$9,0000.06%
FIRST NEW YORK SECURITIES LLC /NY 53,100$19,875,0000.01%
JW Asset Management, LLC 50,254$19,0000.01%
WASHINGTON TRUST Co 410,616$154,0000.01%
JACOBS LEVY EQUITY MANAGEMENT, INC 919,200$344,0000.01%
TWO SIGMA SECURITIES, LLC 37,284$14,0000.01%
Tower Research Capital LLC (TRC) 82,880$31,0000.00%
Modera Wealth Management, LLC 25,000$9,0000.00%
UNITED CAPITAL FINANCIAL ADVISORS, LLC 526,210$195,0000.00%
View complete list of CTI BIOPHARMA CORP shareholders